Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | BAX | Q07812 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PNLIP | P16233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404636 | 0.91 | KMT2A (0.44) | TSPOKMT2ALMNATSHRMEN1 | |
| SCHEMBL8044308 | 0.87 | PTPN1 (0.45) | TSPOKMT2ALMNATSHRLTA4H | |
| SCHEMBL8039723 | 0.86 | PNLIP (0.47) | TSPOKMT2ALMNATSHRTDP1 | |
| SCHEMBL6405714 | 0.86 | ALOX5 (0.47) | TSPOALDH1A1SMN1; SMN2 | |
| SCHEMBL8037899 | 0.85 | MAPT (0.51) | TSPOKMT2ATSHRTDP1LTA4H | |
| SCHEMBL8037870 | 0.84 | LTA4H (0.46) | TSPOKMT2ALMNATSHRTDP1 | |
| SCHEMBL8044175 | 0.83 | TSPO (0.43) | TSPOKMT2ATSHRTDP1ALDH1A1 | |
| SCHEMBL8037882 | 0.83 | LTA4H (0.48) | TSPOLMNATSHRLTA4HSMN1; SMN2 | |
| SCHEMBL8037891 | 0.83 | TSPO (0.40) | TSPOKMT2ALMNATSHRALDH1A1 | |
| SCHEMBL8638319 | 0.82 | TSPO (0.41) | TSPOKMT2ATDP1LTA4HNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | TEIJIN LIMITED | 2005-02-03 | — | — | US | disclosed |
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | TEIJIN LIMITED (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1256341-A1 | CANCER REMEDY COMPRISING ANTHRANILIC ACID DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-0806412-B1 | BENZENE DERIVATIVES | TEIJIN LTD (JP) | 2000-04-05 | — | — | EP | disclosed |
| US-5808144-A | ANTIALLERGENS | TEIJIN LIMITED (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0806412-A1 | BENZENE DERIVATIVES | TEIJIN LIMITED (JP) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | HCCS, BCOR, CBR1 | TSPO 769/4885KMT2A 553/4885LMNA 2685/4885 |
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | CA9, HCCS, CA7 | TSPO 678/4885KMT2A 799/4885LMNA 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.